Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.
Autorzy:
Li Y; a Department of Pharmaceutics , State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University , Nanjing , China . Zhang J; b Department of Oncology , Subei People's Hospital , Yangzhou , China , and. Wang B; b Department of Oncology , Subei People's Hospital , Yangzhou , China , and. Shen Y; a Department of Pharmaceutics , State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University , Nanjing , China . Ouahab A; c Department of Pharmacy , Institute of Medical Sciences, Batna Elhadj Lakhdar University , Batna , Algeria.
Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging.
Autorzy:
Ye J; Department of Radiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, P.R. China. Bhagat SK; Department of Radiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, P.R. China. Li H; Department of Radiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, P.R. China. Luo X; Department of Radiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, P.R. China. Wang B; Department of Oncology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, P.R. China. Liu L; Department of Oncology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, P.R. China. Yang G; Department of Radiology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, P.R. China.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer.
Autorzy:
Liu Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China. Xu F; Department of Thoracic Medicine, Hunan Cancer Center and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410006, P.R. China. Wang Y; Department of Respiratory Medicine, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China. Wu Q; Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, P.R. China. Wang B; Department of Medical Oncology, Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu 225001, P.R. China. Yao Y; Department of Respiratory Medicine, Nanjing General Hospital of Nanjing Military Area Command, Nanjing, Jiangsu 210002, P.R. China. Zhang Y; Department of Respiratory Medicine, Nanjing Chest Hospital, Medical School of Southeast University, Nanjing, Jiangsu 210029, P.R. China. Han-Zhang H; Burning Rock Biotech, Guangzhou, Guangdong 510300, P.R. China. Ye J; Burning Rock Biotech, Guangzhou, Guangdong 510300, P.R. China. Zhang L; Burning Rock Biotech, Guangzhou, Guangdong 510300, P.R. China. Mao X; Burning Rock Biotech, Guangzhou, Guangdong 510300, P.R. China. Zhang Z; Burning Rock Biotech, Guangzhou, Guangdong 510300, P.R. China. Liu J; Burning Rock Biotech, Guangzhou, Guangdong 510300, P.R. China. Zhu L; Department of Internal Medicine, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210009, P.R. China. Guo R; Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, P.R. China.
Pokaż więcej
Źródło:
Oncology letters [Oncol Lett] 2019 Sep; Vol. 18 (3), pp. 3159-3169. Date of Electronic Publication: 2019 Jul 16.
Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
Autorzy:
Yan P; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Yin H; Department of Radiotherapy, Xuzhou Center Hospital, Xuzhou, China. Guo W; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Sun X; Department of Radiotherapy, Jinling Hospital, Nanjing, China. Li F; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Huang S; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Bian X; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Wang F; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Zhang F; Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China. Wang B; Cancer Institute of Northern Jiangsu People's Hospital, Yangzhou, China. Zhou H; Director of Department of Radiotherapy Oncology, Nanjing Benq Medicalcenter, Nanjing, China. Zhou C; Department of Radiotherapy, Xuzhou Center Hospital, Xuzhou, China. Yin L; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Jiang X; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Jiang N; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Wu J; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Liu J; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Song D; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. He X; Department of Radiaotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Sep; Vol. 9 (17), pp. 6166-6172. Date of Electronic Publication: 2020 Jul 12.
Evaluate the Prognosis of MYC/TP53Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
